Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study

BACKGROUND: Achieving optimal symptom control with minimal side effects is a major goal in clinical practice. Dual-agent dopamine receptor agonist (DA) therapy in Parkinson’s disease (PD) may represent a promising approach to treatment, as the combination of different pharmacokinetic/pharmacological...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jong-Min, Chung, Sun Ju, Kim, Jae Woo, Jeon, Beom Seok, Singh, Pritibha, Thierfelder, Stephan, Ikeda, Junji, Bauer, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364324/
https://www.ncbi.nlm.nih.gov/pubmed/25879416
http://dx.doi.org/10.1186/s12883-015-0267-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364324/
https://www.ncbi.nlm.nih.gov/pubmed/25879416
http://dx.doi.org/10.1186/s12883-015-0267-7

Ejemplares similares